Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T (Institute of Hematology & Blood Diseases Hospital)
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CAR-T (Institute of Hematology & Blood Diseases Hospital) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, for the treatment of mantle cell lymphoma (MCL). The therapy involves the ex vivo genetic modification of a patient's T cells to express a chimeric antigen receptor, typically targeting the CD19 antigen expressed on the surface of B-cell malignancies. Once re-infused into the patient, these engineered T cells recognize and induce apoptosis in malignant B cells. It is currently being investigated in Phase 2 clinical trials in China, often as a consolidation therapy following induction regimens involving BTK inhibitors (like zanubrutinib) and immunomodulatory drugs (like lenalidomide) for patients with high-risk or newly diagnosed MCL.
- Other names
- CAR-T-Institute of Hematology & Blood Diseases Hospital, China-mantle cell lymphomaanti-CD19 CAR-T cells (IHBDH)
02
Targets
Beyond the preview
Go deeper on CAR-T (Institute of Hematology & Blood Diseases Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T (Institute of Hematology & Blood Diseases Hospital).